PMID- 19751433
OWN - NLM
STAT- MEDLINE
DCOM- 20091109
LR  - 20220317
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 14
IP  - 5
DP  - 2009 Oct
TI  - Variables influencing outcome of Helicobacter pylori eradication therapy in South 
      China.
PG  - 91-6
LID - 10.1111/j.1523-5378.2009.00718.x [doi]
AB  - BACKGROUND: Therapy combining a proton pump inhibitor (PPI), clarithromycin and 
      either amoxicillin or metronidazole is widely recommended for first-line 
      treatment for Helicobacter pylori infection. The purpose of this study was to 
      examine the outcomes of PPI-containing triple therapy and identify factors 
      influencing the cure rate of H. pylori infection in South China. MATERIALS AND 
      METHODS: H. pylori positive patients with different occupations from 25 hospitals 
      in five provinces of South China were enrolled. They received a PPI, 
      metronidazole and amoxicillin triple therapy for a week. H. pylori eradication 
      was evaluated by (13)C-urea breath test 4 weeks after therapy. Association 
      between H. pylori eradication with occupation, gender, age, educational level, 
      and protocol compliance was evaluated by Logistic regression. RESULTS: Six 
      hundred and seventy-five were enrolled. The intention-to-treat and per-protocol 
      analyses showed overall cure rates of 60% (95% CI = 56.3-63.7%) and 64.5% (95% CI 
      = 60.7-68.3%), respectively. Multivariate logistic regression showed that 
      occupation, gender and protocol compliance were positively associated with the 
      eradication rate (p < .01). The cure rate for those who took 80% or more of the 
      prescribed drugs was 64.5% (95% CI = 60.7-68.3%) versus 14.6% (95% CI = 6-29%, p 
      < .001) for those who took less. Lower eradication rates were also observed in 
      farmers and women. CONCLUSIONS: The eradication rate with a PPI, metronidazole 
      and amoxicillin triple therapy was unacceptably low in South China. These results 
      suggest that studies of the eradication of H. pylori infection in China must take 
      into account antibiotic resistance as well as patient occupation, gender, and 
      protocol compliance. Gastric cancer and peptic ulcer disease are both important 
      in China making methods to effectively and efficiently eradicate H. pylori a 
      priority.
FAU - Cai, Wenzhi
AU  - Cai W
AD  - Department of Preventive Medicine, Fourth Military Medical University, Xi'an 
      City, Shanxi, China.
FAU - Zhou, Liping
AU  - Zhou L
FAU - Ren, Wei
AU  - Ren W
FAU - Deng, Ling
AU  - Deng L
FAU - Yu, Min
AU  - Yu M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/adverse effects/*therapeutic use
MH  - China
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Helicobacter Infections/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/09/16 06:00
MHDA- 2009/11/10 06:00
CRDT- 2009/09/16 06:00
PHST- 2009/09/16 06:00 [entrez]
PHST- 2009/09/16 06:00 [pubmed]
PHST- 2009/11/10 06:00 [medline]
AID - HEL718 [pii]
AID - 10.1111/j.1523-5378.2009.00718.x [doi]
PST - ppublish
SO  - Helicobacter. 2009 Oct;14(5):91-6. doi: 10.1111/j.1523-5378.2009.00718.x.